88Z AI, 8 June — Next-generation AI ultrasound BCI company Huachao Shenkong has completed a hundred-million-yuan angel series financing round, backed by Matrix Partners China, Delian Capital, and Daoyuan Capital. The funds will support the verification and industrialization of its low-intensity focused ultrasound non-invasive brain-computer interface technology, advancing clinical translation for indications such as pain and addiction.
At a glance
- Huachao Shenkong completed a hundred-million-yuan angel series financing with support from Matrix Partners China and Delian Capital.
- Funds will support verification of low-intensity focused ultrasound non-invasive BCI technology and advance clinical translation for pain and addiction.
The update
Huachao Shenkong, a next-generation AI ultrasound brain-computer interface company, recently announced the completion of a hundred-million-yuan angel series financing round. The angel round was led by Matrix Partners China, while the angel+ round was co-led by Delian Capital and Daoyuan Capital. Founded by Li Xin, a PhD from the Chinese Academy of Sciences and former head of GE Healthcare China, the company focuses on low-intensity focused ultrasound non-invasive brain-computer interface technology. The raised capital will be primarily used for technology verification and industrial implementation, aiming to accelerate clinical translation for indications such as pain and addiction, thereby promoting the substantive development of related medical applications.
Sources & editorial note
This article is an AI-assisted synthesis by 88Z AI based on the public sources below. Product claims and availability are attributed to their publishers. It does not represent independent testing or first-hand reporting.
- 36氪Source published
Source dates above refer to the original announcements; the date under the headline is this article’s publication on 88Z AI.